dietari
tryptophan
predominantli
metabolis
via
kynurenin
fig
produc
neuroact
metabolit
kynuren
acid
kyna
kyna
reportedli
act
antagonist
nmethyldaspart
acetylcholin
receptor
furthermor
previou
studi
anim
model
show
elev
kyna
level
brain
impair
cognit
spatial
work
auditori
sensori
rat
abnorm
high
kyna
level
observ
brain
tissu
cerebr
spinal
fluid
csf
patient
therefor
physiolog
control
brain
kyna
level
like
critic
prevent
kyna
produc
kynurenin
kyn
kynurenin
aminotransferas
kat
fig
kat
enzym
requir
pyridox
plp
coenzym
four
kat
isoform
identifi
brain
kyna
predominantli
gener
express
accordingli
play
essenti
role
regul
kyna
level
brain
current
variou
inhibitor
includ
shown
decreas
kyna
level
brain
anim
model
inhibitor
improv
cognit
function
releas
dopamin
acetylcholin
also
act
inhibitor
irrevers
bind
plp
howev
plpdepend
enzym
protein
identifi
irrevers
bind
plp
may
caus
side
effect
exampl
carbidopa
use
treatment
parkinson
diseas
caus
advers
effect
due
irrevers
bind
studi
identifi
novel
inhibitor
differ
inhibitori
mechan
use
micropl
fluoresc
assay
kynurenin
aminotransferas
report
minor
modif
screen
inhibitor
approxim
compound
use
highthroughput
screen
assay
experi
identifi
approxim
candid
inhibitor
data
shown
includ
glycyrrhiz
acid
gl
analogu
glycyrrhetin
acid
ga
carbenoxolon
cbx
fig
basic
structur
three
compound
similar
gl
compris
ga
two
glucuron
acid
wherea
cbx
deriv
gl
also
main
compon
liquoric
compon
tradit
japanes
medicin
previou
report
show
yokukansan
allevi
psycholog
symptom
behaviour
psycholog
symptom
dementia
patient
alzheim
diseas
lewi
improv
cognit
function
patient
senil
thu
gl
ga
cbx
may
inhibitor
efficaci
treatment
mental
disord
evalu
inhibitori
activ
gl
ga
cbx
measur
halfmaxim
inhibitori
concentr
estim
inhibit
constant
ki
gl
ki
ga
ki
cbx
ki
show
high
inhibitori
activ
human
fig
investig
select
gl
ga
cbx
kat
isoform
three
compound
show
inhibitori
activ
mous
none
inhibit
kat
isozym
tabl
indic
select
investig
inhibitori
mechan
gl
ga
cbx
measur
activ
presenc
vari
kyn
concentr
inhibitori
compound
close
gl
ga
cbx
addit
compar
inhibitori
properti
compound
inhibitor
bind
plp
irrevers
use
valu
nm
determin
assay
bind
plp
maximum
reaction
rate
vmax
vari
constant
km
chang
fig
contrast
km
valu
gl
ga
cbx
chang
substrat
concentr
wherea
respect
vmax
valu
vari
condit
fig
result
show
gl
ga
cbx
bind
plp
act
competit
inhibitor
kyn
threedimension
structur
complex
obtain
use
dock
calcul
shown
fig
comparison
also
present
crystal
structur
protein
data
bank
pdb
pdb
id
fig
ligand
locat
ligandbind
pocket
two
molecul
elucid
interact
ligand
magnifi
structur
ligandbind
pocket
fig
identifi
residu
involv
hydrogenbond
format
stack
shown
fig
figur
subunit
b
shown
green
cyan
respect
crystal
structur
kyn
form
hydrogen
bond
b
b
fig
bind
structur
stabilis
interact
aromat
ring
kyn
side
chain
although
gl
form
hydrogen
bond
hydrogen
bond
observ
gl
b
b
fig
yet
stack
interact
may
stabilis
bind
structur
hydrophob
moieti
gl
locat
hydrophob
surfac
compris
carbohydr
chain
gl
locat
outsid
ligandbind
pocket
similarli
hydrophob
moieti
ga
locat
hydrophob
surfac
fig
bind
structur
ga
favour
stabilis
stack
interact
fig
although
ga
form
hydrogen
bond
b
b
hydrogen
bond
b
observ
dock
pose
cbx
similar
valu
gl
also
similar
gl
fig
moreov
residu
requir
stabilis
ligand
bind
hydrophob
effect
stack
interact
conserv
among
gl
analogu
tabl
particular
consid
one
import
residu
ligand
bind
studi
examin
inhibitori
effect
gl
ga
cbx
use
recombin
protein
data
show
gl
ga
cbx
strong
inhibitor
compet
substrat
kyn
previou
studi
indic
increas
kyna
concentr
brain
impair
cognit
spatial
work
auditori
sensori
rat
moreov
abnorm
increas
kyna
observ
brain
tissu
csf
patient
kyna
product
brain
predominantli
catalys
inhibitor
effect
control
kyna
excess
brain
lead
improv
cognit
function
spatial
memori
moreov
mice
display
improv
cognit
function
observ
sever
inhibitor
current
avail
among
irrevers
bind
plp
cofactor
kat
irrevers
bind
plp
may
lead
undesir
inhibit
plpdepend
enzym
protein
sesba
inhibitor
show
select
revers
inhibit
report
valu
compound
human
high
sesba
approxim
studi
recent
develop
inhibitor
oral
administr
prevent
increas
kyna
brain
system
kynurenin
inject
attenu
result
glutam
releas
rat
prefront
mechan
action
competit
noncompetit
select
kat
isoform
remain
unclear
studi
identifi
novel
inhibitor
strong
inhibitori
effect
valu
compound
gl
ga
cbx
low
rang
human
tabl
although
valu
determin
basic
condit
obtain
optim
physiolog
condit
ph
confirm
valu
gl
ga
cbx
human
almost
respect
also
show
compound
highli
select
among
kat
isozym
compet
substrat
kyn
furthermor
predict
complex
structur
use
dock
calcul
locat
gl
ga
cbx
surfac
aromat
ring
kyn
dock
structur
suggest
high
inhibitori
activ
gl
analogu
reflect
larger
hydrophob
interfac
agreement
hydrophob
effect
common
among
inhibitor
describ
previou
furthermor
form
hydrogen
bond
ga
hydrogen
bond
inhibitor
complex
also
form
complex
contrast
hydrogen
bond
uniqu
dock
structur
gl
cbx
yet
carbohydr
chain
gl
locat
outsid
ligandbind
pocket
like
affect
affin
inhibitor
mere
alter
plp
bind
risk
side
effect
may
minimis
comparison
inhibit
form
coval
adduct
plp
addit
compar
sesba
exhibit
revers
inhibitori
effect
gl
ga
cbx
potent
inhibitori
activ
therefor
success
identifi
three
new
inhibitor
superior
inhibitor
present
experi
show
inhibitori
effect
gl
ga
cbx
less
potent
mice
human
tabl
differ
may
aris
differ
conserv
residu
among
speci
accordingli
sequenc
align
mous
rat
human
report
pellicciari
et
al
sequenc
variant
human
rat
associ
rel
inhibitori
activ
comput
dock
studi
show
hydrophob
effect
human
import
interact
gl
analogu
tabl
among
residu
particip
bind
human
gl
analogu
substitut
ser
mous
specul
differ
undermin
inhibitori
effect
gl
analogu
mous
also
demonstr
among
four
kat
isoenzym
gl
ga
cbx
select
inhibit
tabl
kyna
predominantli
gener
brain
specif
inhibitor
eagerli
await
rossi
f
et
al
solv
crystal
structur
human
show
import
structur
differ
could
exploit
ration
design
highli
select
particular
human
share
overal
sequenc
ident
structur
analys
activ
site
reveal
strike
differ
substrat
bind
review
also
demonstr
hydrophob
interact
gl
analogu
similar
inhibitor
report
previou
studi
suggest
addit
uniqu
residu
interact
gl
analogu
tabl
residu
may
involv
select
inhibitori
effect
gl
analogu
human
although
mechan
gl
analogu
specif
inhibit
remain
unknown
structur
differ
kat
isozym
uniqu
residu
interact
gl
analogu
like
mediat
specif
henc
present
observ
use
inform
ration
design
specif
competit
inhibitor
inhibitor
therapeut
potenti
psychiatr
disord
must
pass
blood
brain
barrier
bbb
cbx
fail
pass
bbb
previou
preclud
consider
contrast
gl
main
constitu
liquoric
compris
molecul
ga
two
glucuron
acid
metabolis
ga
microbiota
intestin
follow
oral
administr
ga
absorb
henc
studi
warrant
clarifi
inhibitori
effect
gl
anim
model
psychiatr
diseas
liquoric
ingredi
yokukansan
tradit
japanes
kampo
medicin
yokukansan
effect
treatment
patient
symptom
patient
behaviour
psycholog
symptom
dementia
due
alzheim
diseas
lewi
yet
yokukansan
multipl
ingredi
clear
respons
therapeut
effect
yokukansan
reportedli
inhibit
glutam
releas
zincdefici
exert
neuroprotect
effect
accommod
dysfunt
glutam
transport
inhibitori
effect
yokukansan
howev
clarifi
studi
requir
evalu
involv
inhibit
neuroprotect
therapeut
effect
yokukansan
patient
psychiatr
disord
pharmacolog
agent
gl
antivir
inhibit
hepat
tumour
follow
improv
solubl
glycyrrhizin
salt
diammonium
glycyrrhizin
dipotassium
glycyrrhizin
antiinflammatori
effect
similar
furthermor
drug
contain
gl
stronger
neominophagen
c
glycyron
tablet
minophagen
pharmaceut
tokyo
japan
commerci
avail
use
treat
chronic
liver
thu
use
gl
inhibitor
treatment
schizophrenia
repres
drug
reposit
process
new
therapeut
use
exist
drug
discov
conclus
demonstr
gl
ga
cbx
inhibitor
inhibitor
select
potent
oper
mechan
substrat
competit
thu
find
suggest
drug
contain
gl
excel
candid
drug
reposit
treatment
schizophrenia
gl
gl
dipotassium
salt
ga
dimethyl
sulfoxid
dmso
purchas
fujifilm
wako
pure
chemic
ltd
osaka
japan
cbx
purchas
abcam
uk
compound
dissolv
dmso
method
carri
accord
relev
guidelin
regul
protocol
anim
experi
approv
institut
anim
care
use
committe
fujita
health
univers
human
cdna
synthesis
human
blood
peripher
leukocyt
total
rna
takara
japan
use
revertra
ace
kit
toyobo
osaka
japan
mous
cdna
synthesis
total
rna
extract
whole
brain
mice
use
revertra
ace
kit
cdna
amplifi
use
polymeras
chain
reaction
specif
primer
amplifi
cdna
clone
pfastbac
htc
vector
invitrogen
carlsbad
ca
usa
transform
escherichia
coli
cell
pfastbac
htc
vector
contain
target
gene
transform
e
coli
cell
baculoviru
transfer
vector
transfect
insect
cell
recombin
enzym
express
infect
cell
hightitr
baculoviru
cell
pellet
centrifug
dissolv
mm
phosphat
buffer
ph
contain
mm
nacl
mm
imidazol
sonic
cell
lysat
centrifug
g
min
recombin
enzym
supernat
ad
preequilibr
ninta
resin
qiagen
enzymeresin
complex
transfer
column
wash
buffer
contain
mm
nacl
mm
imidazol
mm
phosphat
buffer
ph
recombin
enzym
elut
buffer
contain
mm
nacl
mm
imidazol
mm
phosphat
ph
enzym
fraction
pool
base
puriti
determin
use
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
desalt
use
column
ge
healthcar
uk
recombin
human
purchas
origen
technolog
inc
usa
highthroughput
screen
assay
inhibitor
human
conduct
use
micropl
fluoresc
assay
kynurenin
minor
modif
assay
enzym
activ
measur
black
untreat
plate
human
reaction
mixtur
contain
recombin
human
mm
lkyn
mm
acid
plp
tween
mm
amp
buffer
ph
ad
plate
contain
compound
use
multidrop
dispens
thermo
fisher
scientif
usa
compound
librari
compris
compound
drug
discoveri
initi
univers
tokyo
compound
librari
includ
divers
compound
pilot
screen
known
bioactiv
compound
compound
dissolv
dilut
dmso
final
concentr
reaction
mixtur
incub
h
room
temperatur
aliquot
mm
zinc
acet
ph
ad
directli
use
multidrop
dispens
fluoresc
intens
kyna
measur
use
arvo
x
multi
label
reader
perkinelm
usa
excit
wavelength
nm
emiss
wavelength
nm
assay
qualiti
valid
calcul
z
factor
assay
identifi
approxim
candid
inhibitor
potent
inhibitori
activ
compound
candid
compound
valid
quadrupl
enzym
activ
assay
inhibitori
activ
identifi
compound
measur
use
enzym
activ
assay
describ
reaction
mixtur
contain
recombin
human
mm
lkyn
mm
sodium
pyruv
plp
tween
inhibitor
variou
concentr
mm
amp
buffer
ph
human
mous
reaction
mixtur
contain
recombin
human
mous
mm
lkyn
mm
acid
plp
tween
inhibitor
variou
concentr
mm
amp
buffer
ph
follow
addit
aliquot
mm
zinc
acet
fluoresc
intens
kyna
measur
use
arvo
x
multi
label
reader
perkinelm
usa
enzym
activ
measur
use
high
perform
liquid
chromatographi
hplc
analys
reaction
product
briefli
reaction
mixtur
contain
recombin
human
mm
lkyn
mm
sodium
pyruv
plp
tween
inhibitor
variou
concentr
mm
amp
buffer
ph
reaction
mixtur
contain
recombin
human
mm
lkyn
mm
acid
plp
tween
inhibitor
variou
concentr
mm
tri
buffer
ph
reaction
mixtur
incub
h
reaction
stop
ad
perchlor
acid
ratio
kyna
content
reaction
mixtur
determin
use
hplc
shimadzu
kyoto
japan
follow
isocrat
elut
reversephas
column
tskgel
mm
id
mm
l
tosoh
tokyo
japan
use
mobil
phase
contain
mm
sodium
acet
acetonitril
ph
adjust
flow
rate
mlmin
kyna
detect
use
fluoresc
detector
excit
wavelength
nm
emiss
wavelength
nm
determin
steadi
state
kinet
paramet
substrat
lkyn
reaction
mixtur
contain
recombin
human
mm
plp
tween
lkyn
concentr
mm
gl
ga
cbx
nm
respect
follow
incub
min
reaction
stop
ad
perchlor
acid
ratio
kyna
concentr
measur
use
hplc
method
describ
doubl
reciproc
plot
use
determin
type
inhibit
competit
inhibit
constant
ki
gl
ga
cbx
calcul
use
global
fit
formula
graphpad
prism
follow
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
rm
v
rm
vmax
ast
rm
rm
km
rm
ob
rm
rm
rm
km
rm
ob
rm
km
time
rm
rm
ki
end
document
kmob
ki
v
initi
veloc
vmax
maximum
veloc
substrat
concentr
km
constant
inhibitor
concentr
ki
valu
calcul
use
global
fit
formula
follow
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
rm
vmax
rm
inh
rm
vmax
rm
rm
ki
rm
rm
km
rm
ob
rm
vmax
rm
inh
time
rm
rm
km
rm
end
document
vmaxinhvmax
ki
km
vmaxinh
maximum
enzym
veloc
concentr
inhibitor
valu
determin
nonlinear
curv
fit
use
graphpad
prism
statist
analys
perform
use
graphpad
prism
comput
dock
trial
perform
use
gold
softwar
default
threedimension
structur
form
retriev
protein
data
bank
pdb
pdb
id
crystal
structur
includ
substrat
kyn
coenzym
analogu
pyridoxamin
pmp
kyn
remov
plp
substitut
pmp
calcul
substitut
plp
structur
optimis
use
gaussian
inc
wallingford
ct
g
p
miss
hydrogen
atom
pdb
structur
comput
ad
use
herm
http
wwwccdccamacuk
centr
kyn
defin
centr
ligandbind
site
bind
site
radiu
set
ligand
structur
optimis
calcul
level
plp
